Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes after endoscopic eradication therapy for dysplastic and T1a adenocarcinoma related Barrett's esophagus: higher rate of late dysplastic recurrence with radio-frequency ablation monotherapy.
He T, Sundararajan V, Clark NJ, Tsoi EH, Thompson AJ, Holt BA, Desmond PV, Taylor AC. He T, et al. Among authors: holt ba. Gastrointest Endosc. 2025 Jan 25:S0016-5107(25)00050-1. doi: 10.1016/j.gie.2025.01.026. Online ahead of print. Gastrointest Endosc. 2025. PMID: 39870246
Time-restricted versus standard-duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trial.
Broers AEC, Meijer E, van der Holt B, de Jong CN, Nur E, van Sluis GL, Choi G, van Gelder M, Maertens JA, Kuball J, Deeren D, Visser-Wisselaar HA, Meulendijks LAHM, Cornelissen JJ; HOVON Stem Cell Transplantation Working Group. Broers AEC, et al. Among authors: van der holt b. Hemasphere. 2024 Dec 11;8(12):e70040. doi: 10.1002/hem3.70040. eCollection 2024 Dec. Hemasphere. 2024. PMID: 39665067 Free PMC article.
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014).
Lugtenburg PJ, Nully Brown P, van der Holt B, de Jongh E, Zijlstra JM. Lugtenburg PJ, et al. Among authors: van der holt b. Eur J Cancer. 2025 Jan;214:115144. doi: 10.1016/j.ejca.2024.115144. Epub 2024 Nov 22. Eur J Cancer. 2025. PMID: 39615333 No abstract available.
Author Correction: Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device.
Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Soltani A, Gazit E, Salis F, Alcock L, Aminian K, Becker C, Bertuletti S, Brown P, Buckley E, Cantu A, Carsin AE, Caruso M, Caulfield B, Cereatti A, Chiari L, D'Ascanio I, Garcia-Aymerich J, Hansen C, Hausdorff JM, Hiden H, Hume E, Keogh A, Kluge F, Koch S, Maetzler W, Megaritis D, Mueller A, Niessen M, Palmerini L, Schwickert L, Scott K, Sharrack B, Sillén H, Singleton D, Vereijken B, Vogiatzis I, Yarnall AJ, Rochester L, Mazzà C, Eskofier BM, Del Din S; Mobilise-D consortium. Kirk C, et al. Sci Rep. 2024 Nov 21;14(1):28878. doi: 10.1038/s41598-024-79454-4. Sci Rep. 2024. PMID: 39572620 Free PMC article. No abstract available.
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.
Mai EK, Nogai A, Lokhorst HM, van der Holt B, Zweegman S, Weisel KC, Croockewit S, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Bos GMJ, Brossart P, Ypma P, Hanoun C, Bertsch U, Hielscher T, Salwender HJ, Scheid C, Goldschmidt H, Sonneveld P. Mai EK, et al. Among authors: van der holt b. Hemasphere. 2024 Nov 20;8(11):e70052. doi: 10.1002/hem3.70052. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39569355 Free PMC article. No abstract available.
514 results